This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced colorectal cancer
The age is 18 to 75 years (including boundary values) and the gender is not limited;
The standardized systemic treatment received by the patient must be in accordance with the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Treatment of Colorectal and Gastric Cancer, 2024 Edition;
Hemoglobin (Hb) ≥ 90 g/L;
Neutrophil count (Absolute neutrophil count, ANC) ≥ 1.5 x 10^9/L;
Presence of brain metastases;
Patients who have previously received or are awaiting an organ transplant;
Toxicity due to prior therapy not stabilized or recovered to ≤ grade 1 (except in cases judged by the investigator to be not clinically significant);
Plasmapheresis (e.g., pleural effusion, abdominal effusion, pericardial effusion) with symptoms of compression that cannot be controlled with treatment;
Beijing Immunochina Medical Science & Technology Co., Ltd.
Lead sponsor
Peking University Cancer Hospital & Institute
Collaborator